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ABSTRACT The major glycoprotein, G, of human respi-
ratory syncytial (RS) virus is a M, 84,000-90,000 species that
has about 60% of its mass contributed by carbohydrate, most
of which is in the form of O-linked oligosaccharides. The G
protein contains neither a hydrophobic N-terminal signal
sequence nor a hydrophobic C-terminal anchor region. In-
stead, its amino acid sequence reveals only one region with
significant hydrophobic character, which is between residues
38 and 66. In order to study the synthesis, processing, and
functions of this unusual viral glycoprotein, full-length cDNA
copies of the G protein mRNA were inserted into the DNA
genome of vaccinia virus (VV) in a position that was adjacent
to a strongW promoter and within theW gene for thymidine
kinase (TK). The resulting TK- recombinant viruses were
selected, plaque-purified, and characterized by Southern blot
analysis of restriction enzyme digests of the viral DNA.
Recombinant RNA transcripts that contained both G-specific
and W-specific sequences accumulated in cells infected with
recombinant viruses having the G protein gene in the positive
orientation. The translation product of these transcripts in
infected cells was a Mr 84,000-90,000 glycoprotein that was
indistinguishable from authentic RS virus G protein. It could
be detected in cell lysates after metabolic labeling with
[3H]glucosamine and was immunoprecipitated by anti-RS-
virus antiserum. Immunofluorescence studies showed that the
G protein accumulated intracellularly with the perinuclear
distribution that is characteristic of newly synthesized
glycoproteins. Furthermore, the protein was also clearly de-
tectable on the surface of recombinant-infected cells, showing
that it was transported to and inserted into the plasma
membrane.
Human respiratory syncytial (RS) virus is an important
human pathogen that causes severe lower respiratory tract
disease, particularly among young children (1). The related
virus, bovine RS virus, causes severe respiratory disease in
cattle (2). No effective vaccine has been developed for either
virus; moreover, natural infection with the human virus
frequently fails to confer immunity. Thus, recurrent epidem-
ics occur during which human RS virus is a major cause of
hospitalization of children with lower respiratory tract dis-
ease (1, 2).
Progress in understanding the molecular biology of RS
virus and the role of individual proteins in infection and
immunity has been slow because the virus replicates poorly
in cell culture and is extremely labile, which makes it difficult
to obtain adequate quantities of the virus or viral proteins for
experimentation. Recently, however, as a result of cDNA
cloning, substantial progress has been made in our knowledge
of the molecular biology of human RS virus (3-5). Classified
as genus Pneumovirus within the Paramyxoviridae family (6),
human RS virus has a genome of single-stranded, negative-
sense RNA of about Mr 5,600,000 that encodes 10 unique
viral proteins (4, 7-12). In order to understand the pathogen-
esis of human RS virus infection and, in particular, to study
the interaction of the virus with the immune system, we have
concentrated on the structure and function of the two major
viral antigens, the glycoproteins F and G (10, 11).
The G protein of human RS virus lacks the hemagglutina-
tion and neuraminidase activities found in the second (HN)
glycoproteins of other paramyxoviruses (13) and contains
structural features that make it unique among the known viral
glycoproteins (11). For example, the predicted sequence of
its 298 amino acids reveals no N-terminal signal sequence nor
C-terminal anchor sequence but only a single hydrophobic
region between amino acid residues 38 and 66. If this is a
transmembrane region, its location suggests that the G
protein may be oriented with its C terminus on the external
side of the membrane, like the influenza virus neuraminidase
(14, 15). However, unlike the latter protein, the mature RS
virus G protein contains more than 60% of its mass as
carbohydrate, most of which is comprised of O-linked oligo-
saccharide chains (11, 16). Serine and threonine residues,
which provide the sites for O-glycosylation, constitute 30.6%
of the protein. In addition, four potential sites for the
attachment of N-linked oligosaccharides have been identi-
fied, and at least some ofthem appear to be glycosylated (11,
16).
The unusual structure of this glycoprotein raises many
fundamental questions concerning the mechanisms of its
synthesis, membrane insertion and anchoring, N- and 0-
glycosylation, and transport to the plasma membrane. To
address these questions and to examine the role of the G
protein in the immune response to RS virus infection, we
have inserted full-length cDNA copies of the G protein into
eukaryotic expression vectors derived from vaccinia virus
(VV) (17, 18). This type ofvector has two distinct advantages
for our purposes. First, transcripts from recombinant VV
vectors are not exposed to the cellular splicing enzymes;
thus, they avoid the risk of inappropriate splicing, which can
otherwise occur with RNA sequences that have evolved
exclusively in a cytoplasmic environment. Second, the VV
recombinants that we have constructed are live, nondefective
viruses that provide a highly efficient system for the delivery
and expression of foreign genes by using either cell-free
transcription-translation systems (19), animal cells in cul-
ture, or whole animals (20, 21). Here we report the construc-
tion and characterization of recombinant VV vectors that
contain cDNA copies of the human RS virus G protein gene.
The synthesis, maturation, and cell-surface expression of the
Abbreviations: RS virus, respiratory syncytial virus; wt, wild type;
VV, vaccinia virus; moi, multiplicity of infection; TK, thymidine
kinase; kb, kilobase(s).
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G protein in cells infected with these vectors were found to
be indistinguishable from those occurring during infection
with RS virus itself.
MATERIALS AND METHODS
Cells, Viruses, and Plasmids. The growth of human RS
virus (A2 strain) in HEp-2 cells and the growth of VV (WR
strain) in HeLa cells have been described (7, 22). Thymidine
kinase-negative TK- 143 cells (kindly provided by B. Moss,
National Institutes ofHealth) were maintained as monolayers
in minimal essential medium containing 5% fetal bovine
serum and 20 ,Ag of 5-bromo-2'-deoxyuridine per ml. Esch-
erichia coli plasmids carrying the HindIII F and HindIII J
fragments of VV DNA in the HindIII site of pBR322 were
generously provided by D. Panicali (New York State Public
Health Laboratories, Albany) and B. Moss, respectively.
The plasmid pGS20, which was used as a source of the
7.5-kDa promoter fragment (18) was also provided by Moss.
Digestions with restriction enzymes and BAL-31 exonucle-
ase, generation of blunt ends, phosphorylation of linker and
adaptor oligonucleotides, ligation of DNA fragments, and
transformation ofE. coliHB101 were performed as described
by Maniatis et al. (23). TK- VV recombinants were isolated
as described by Mackett et al. (18) and were screened by the
quick-blot procedure of Gillespie and Bresser (24).
Analyses of Gene Expression. Blot-hybridization analyses
ofRNA (7) and metabolic labeling and immunoprecipitation
of proteins (11) were performed as described before. For
analyses using indirect immunofluorescence, baby hamster
kidney (BHK) cells were grown as monolayers on multi-
chambered slides (Miles Scientific). The monolayers were
infected with RS virus at a multiplicity of infection (moi) of
5 or with the recombinants or wild-type (wt) VV at an moi of
30. At 24 hr (RS virus-infected) or 4 hr (recombinants and wt
VV-infected) after infection, the slides were washed twice in
phosphate-buffered saline (PBS; 0.137 M NaCl/0.0018 M
CaCl2/0.008 M Na2HPO4/0.0015 M KH2PO4). For cell-
surface staining, the cells were fixed for 15 min at room
temperature with 1% formalin in PBS and then washed once
in PBS. Five microliters ofRS virus-specific horse antiserum
(Flow Laboratories) were added to each chamber, and the
slides were incubated at 37°C for 30 min. The slides were then
washed three times in PBS for 2 min per wash. Thirty
microliters of fluorescein isothiocyanate-conjugated anti-
horse IgG antiserum was added to each chamber, and the
slides again were incubated at 37°C for 30 min. The slides
were washed as before, mounted with 20% glycerol in PBS
containing 1% bovine serum albumin, and examined with a
Leitz fluorescent microscope. For intracellular staining, the
cells were first permeabilized by fixing for 5 min in
methanol/acetone, 1:1 (vol/vol), at -20°C, washed once in
PBS, incubated with the two antisera, and mounted as
described for the detection of surface fluorescence.
RESULTS
Construction and Characterization of Recombinant W
Vectors. Foreign DNA sequences can be inserted into the
genome of VV by homologous recombination (17). The VV
gene for TK (25, 26) provides an ideal insertion site because
of the ease with which TK- recombinants can be selected
(27). This strategy has been exploited in the successful
expression of several genes of viral and nonviral origin
(28-32). However, since VV promoters exist that are thought
to be much more active than the TK promoter (18), it is
advantageous to transplant a strong VV promoter to a site
within the TK gene and to insert the foreign DNA sequences
adjacent to it (27). We have used two different VV promoters
for this purpose: one, the F promoter, has been shown to
direct transcription across the unique BamHI site in the
HindIII F fragment of VV DNA (17); the other, the 7.5-kDa
promoter, directs transcription of the gene for a 7.5-kDa
protein of unknown function, both early and late in infection
(33). DNA fragments bearing these promoters and having two
EcoRI sticky ends were inserted into the EcoRI site in the
middle of the VV TK gene.
A full-length cDNA copy of the RS virus G protein gene
(clone 2B-16) (11) was subjected to BAL-31 exonuclease
digestion to remove the G&C tails and was inserted into the
unique BamHI sites in the vector plasmids by using BamHI
linkers. The recombinant plasmids were purified and recom-
bined into VV to yield recombinant viruses with the genome
structures illustrated in Fig. 1.
Recombinant TK- viruses were selected, plaque-purified,
and examined by analysis of restriction enzyme digests of
their DNA. The presence and location of the G protein gene
within the DNA genomes of the recombinant viruses were
confirmed by digestion with BamHI or HindIII restriction
endonucleases and Southern blot analyses of the separated
DNA fragments (35, 36). The 4.5-kilobase (kb) HindIII J
fragment of wt VV DNA (which carries the TK gene) was
replaced in the recombinants by a largerfragment ofabout 6.7
kb in vAG201 and 202 and of about 5.8 kb in vAG301 (data
not shown). Unlike the original HindIII J fragment, these new
fragments hybridized to an RS virus G protein probe,
indicating the presence of the RS virus sequences. Since the
F and 7.5-kDa promoter fragments contained about 1.2 and
0.28 kb, respectively, and the RS virus fragment contained
0.95 kb, the observed sizes of the recombinant DNA frag-
ments were exactly in accordance with expectation. BamHI
digestion of the recombinant DNAs revealed only the ex-
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FIG. 1. Schematic representation of the genome
structures of the recombinant viruses vAG201 and
B vAG301. The HindIII map of the VV genome is shown,
with an expanded view of the 1.85-kb HindllI-Xho I
subfragment oftheW HindIII fragment J that contains
the TK gene. The position and orientation of the
transplanted promoter fragments and inserted RS virus
G protein cDNA are indicated for vAG201 and vAG301
Xho (not to scale). Recombinants vAG201 and vAG202
contained a 1.2-kb EcoRI-BamHI promoter fragment
derived from the VV HindIII fragment F (17); vAG301
contained a 0.28-kb promoter fragment from the VV
7.5-kDa protein gene (34). The RS virus G protein
cDNA lacked the first nine nucleotides from the 5' end
of the G mRNA but contained an intact 3' end followed
by 17 deoxyadenylate residues and several deoxycy-
tidylate residues. In vAG202, the orientation of the RS
virus cDNA was reversed relative to the transplanted
F promoter.
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pected 0.95-kb G-specific fragment in each case (data not
shown).
Transcriptional Analysis of Recombinants by Blot Hybrid-
ization. Expression of the RS virus gene was examined at the
transcriptional level by blot-hybridization analysis using as
probes DNA corresponding to the RS virus G protein gene or
to a 1.85-kb HindIII-Xho I subfragment of VV HindIII J that
contains the TK gene (see Fig. 2 Lower). Fig. 2 Upper shows
the results of this analysis with recombinants vAG201,
vAG202, and vAG301. Early in infection with wt VV, two
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FIG. 2. (Upper) Analysis of recombinant transcripts by blot
hybridization. Cytoplasmic RNA was isolated from infected HEp-2
cells either 12 hr (RS virus infection) or 6 hr (wt VV and recombinant
infections) after infection. Cycloheximide (100 ug/ml) was added to
the VV- and recombinant-infected cells at the time of infection. The
RNAs were purified by phenol extraction and ethanol precipitation,
separated by electrophoresis on an agarose-urea gel at pH 3.5, and
then blotted onto diazobenzyloxymethyl paper (7). 32P-labeled,
nick-translated plasmid DNA probes corresponding to the RS virus
G gene (Left) and the 1.85-kb HindIII-Xho I fragment encompassing
the VV TK gene (Right) were hybridized to the blots. Lanes: RS, RS
virus-infected; 201, recombinant vAG201-infected; 202, recombinant
vAG202-infected; 301, recombinant vAG301-infected; VV, wt VV-
infected; UN, uninfected cells. (Lower) Schematic representation of
the DNA region surrounding the VV TK gene and its corresponding
early transcripts in wt VV DNA and in recombinants vAG201 and
vAG301. Schematic poly(A) tails indicate the 3' ends of the tran-
scripts and approximate transcript sizes are shown in kb. P repre-
sents the F and 7.5-kDa promoter fragments (not drawn to scale) in
vAG201 and -301, respectively.
TK gene: a 0.6-kb mRNA, which is the major TK message,
and a 1.8-kb mRNA, which maps just downstream of the TK
gene (Fig. 2 Lower) (ref. 37; D. Hruby, D. Albright, and
L.A.B., unpublished results). A minor species ofabout 2.5 kb
appears to be the result of transcriptional readthrough be-
tween these two genes. In cells infected with the recombi-
nants, the 1.8-kb mRNA was unaltered, but the 0.6-kb TK
mRNA was replaced by a smaller species of about 0.5 kb. In
addition, cells infected with recombinants vAG201 and -301
contained new species ofRNA of about 1.3-1.4 kb in length.
These new RNAs hybridized not only to the VV-specific
probe but also to the RS virus G-specific DNA, indicating
that they resulted from transcription ofthe RS virus G protein
gene and across one of the RS virus-VV junctions. Analyses
using probes that were specific for either the 5' or the 3' end
of the TK gene indicated that these recombinant mRNAs
spanned the RS virus gene and the 3' half of the VV TK gene
and probably terminated at the VV TK termination and
polyadenylylation signal (Fig. 2 Lower). The minor larger RS
virus-specific transcripts probably result from readthrough to
the end of the 1.8-kb VV gene. The lack of recombinant
transcripts corresponding in size to the G mRNA from RS
virus-infected cells indicates that the RS virus termination
and polyadenylylation signal was ignored by the VV DNA-
dependent RNA polymerase. No new VV-specific RNAs nor
any RS virus-specific species were detected in cells infected
with vAG202 (Fig. 2 Upper). This recombinant contained the
G sequence in the negative orientation with respect to the
transplanted F promoter.
Analysis of Proteins Made in Recombinant-Infected Ceils.
The proteins synthesized in cells infected with the recombi-
nants were examined by metabolic labeling with either
[3H]glucosamine or tritiated amino acids and electrophoresis
on NaDodSO4/polyacrylamide gels. Two major glycopro-
teins were detected in cells infected with recombinants
vAG201 and -301: a Mr 82,000 species that was also present
in cells infected with wt VV and a new Mr 84,000-90,000
glycoprotein that comigrated exactly with authentic RS virus
G protein (Fig. 3). Immunoprecipitation using anti-RS-virus
antiserum demonstrated unambiguously that the latter spe-
cies was the RS virus G protein, and its electrophoretic
mobility suggested that it was fully glycosylated. The same
protein also could be detected in immunoprecipitates of
recombinant-infected cells that were labeled with [3H]thre-
onine and [3H]proline, two amino acids that are particularly
abundant in G (11) (not shown).
The level ofG protein that was expressed varied among the
recombinants. Under optimum conditions, cells infected with
vAG301 synthesized the G protein at a maximum rate that
was comparable to that observed in cells infected with wt RS
virus. On the other hand, vAG201 directed lower levels ofG
synthesis than did vAG301 (Fig. 3), despite the more abun-
dant transcription. As expected, vAG202 which contained
the G gene in the negative orientation with respect to the F
promoter and which failed to transcribe the RS viral se-
quences (Fig. 2 Upper), also failed to direct the synthesis of
detectable amounts of G protein (Fig. 3).
Expression ofthe RS virus G protein was also examined by
indirect immunofluorescence of recombinant-infected per-
meabilized and nonpermeabilized fixed cells. The former
procedure, which reveals the intracellular distribution of the
maturing glycoprotein, showed that it accumulated in the
perinuclear region of recombinant-infected cells (Fig. 4a and
b). Such a localization is characteristic of maturing glyco-
proteins, which accumulate in the Golgi apparatus. This is
also thought to be the subcellular site at which O-glycosyl-
ation occurs (38). The distribution of fluorescence in the RS
virus-infected cells shown in Fig. 4b and d does not reflect
exclusively the location of the G protein because the antise-
rum used was reactive with all ofthe major RS viral proteins.
" -I,. .M
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FIG. 3. Analysis by NaDodSO4/polyacrylamide gel electropho-
resis of the glycoproteins made in infected cells. HEp-2 cells were
infected with wt RS virus or with wt VV or the indicated recombi-
nants (moi = 2-5). The infected cells were labeled by incorporation
of [3H]glucosamine (100 ACi/ml) from 24 to 27 hr (RS virus infection)
or from 3 to 6 hr (wt and recombinant VV infections) after infection.
The labeled proteins were analyzed by electrophoresis on 12%
NaDodSOW/polyacrylamide gels after immunoprecipitation with
horse anti-RS-virus antiserum. A fluorogram of the dried gel is
shown. The glycoprotein band visible in every lane is a cellular
glycoprotein that was sometimes present in the immunoprecipitates.
Lanes: UN, uninfected cells; RS, RS virus-infected cells; 301, 201,
and 202, cells infected with recombinants vAG301, -201, and -202,
respectively; VV, wt VV-infected cells. The positions of the mature
RS virus G protein and the two subunits of the RS virus F protein are
shown.
However, experiments using a mono-specific anti-G protein
antiserum showed that the intracellular distributions of G
were identical in RS virus and recombinant-infected cells (not
shown).
G protein synthesized in recombinant-infected cells was
transported to and expressed on the plasma membrane as
shown by indirect immunofluorescence of fixed nonperme-
abilized cells (Fig. 4c). The cell-surface distribution of the
protein was similar to that seen with RS virus-infected cells
(Fig. 4d). A comparison of the appearance of recombinant-
infected cells when viewed under fluorescence and phase-
contrast optics showed that essentially 100%o of the cells
infected at an moi of 30 plaque-forming units per cell
expressed the G protein on their surface (Fig. 4c and e,
respectively).
DISCUSSION
The results presented above demonstrate that recombinant
VV vectors containing cDNA copies of the RS virus G
protein gene can express the glycoprotein in a form that is
indistinguishable in electrophoretic mobility, antigenicity,
and cellular distribution from the authentic RS virus G
protein. The ability to synthesize and examine this unusual
viral glycoprotein out of the context of an RS virus infection
will greatly facilitate studies of its function in infection,
mechanism of maturation and transport to the cell surface,
and potential role in the immunity to infection. Furthermore,
since it is difficult to propagate RS virus, this expression
system provides a relatively easy means to produce signifi-
cant quantities of this viral glycoprotein.
We have compared G expression from vectors that utilize
two different promoters. The recombinant that used the
7.5-kDa promoter expressed higher initial levels ofG protein
and maintained this expression later into the VV replication
cycle. This is consistent with the fact that the 7.5-kDa
promoter fragment contains overlapping early and late pro-
FIG. 4. Intracellular localization and cell-surface detection ofRS
virus G protein in baby hamster kidney cells infected with recom-
binant viruses. Baby hamster kidney cell monolayers on multicham-
bered tissue culture slides were infected with RS virus, recombi-
nants, or wt VV. Permeabilized cells (a, b, and f) were stained for
intracellular RS viral antigens, and fixed nonpermeabilized cells (c
and d) were stained for cell-surface expression of RS viral antigens
by indirect immunofluorescence using RS virus-specific first anti-
body and fluorescein-conjugated second antibody. (a) vAG201-
infected cells. (b and d) RS virus-infected cells. (c) vAG301-infected
cells. (e) Phase-contrast photograph of the vAG301-infected cells
whose surface fluorescence is shown in c. (f) wt W-infected cells.
Cell-surface staining of live cells gave results similar to those
obtained from fixed nonpermeabilized cells.
moter sites (33). Within a few hours of infection with this
recombinant (vAG301), the rate of G protein synthesis was
comparable to the peak rates achieved during wt RS virus
infection. Surprisingly, however, the recombinant that used
the F promoter (vAG201) expressed consistently higher
levels of RS virus-specific mRNA (Fig. 2 Upper). This
apparent difference in the specific translational activity ofthe
recombinant transcripts from the two VV promoters is
probably due to differences in the VV-specific nucleotide
sequences at their 5' ends.
Another unexpected aspect ofthe mRNA analyses was the
relative abundance of the recombinant transcripts and the
truncated TK transcripts. On the basis of experiments in
which the 7.5-kDa and TK promoters were used to drive
expression of the chloramphenicol acetyltransferase gene,
Mackett et al. (18) concluded that the former promoter was
10-20 times more active than the latter. However, the
abundance of the truncated TK transcripts in cells infected
with vAG201 or vAG301 exceeded that of the recombinant
transcripts (Fig. 2 Upper), suggesting that some of the
difference in expression of the chloramphenicol acetyltrans-
ferase gene may have been due to translational effects and
that the relative transcriptional strengths of these promoters
should be reevaluated.
The transcripts from the TK promoter in vAG201, -202,
and -301 were truncated about 200 nucleotides into the
transplanted F promoter fragment or 250 nucleotides into the
7.5-kDa promoter fragment. This presumably reflects the
operation of natural VV transcriptional termination signals at
these positions. The total lack of recombinant transcripts in
cells infected with the negative construct, vAG202, is less
readily explained. Since the radioactive probes were not
Biochemistry: Ball et aL
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strand-specific, recombinant transcripts of either sense
would have been detected. We suggest that the complement
ofsome sequence at or near the 3' end ofthe RS virus G gene,
perhaps the poly(dC) or poly(dA) tracts, completely blocks
the further extension of transcripts from the F promoter.
Whatever the explanation, the normal synthesis of the
downstream 1.8-kb transcript under these circumstances
proves that it is made independently of the TK mRNA and
not processed from the 2.5-kb readthrough transcript as
previously thought possible (37).
In addition to the mature G protein, some minor glycosyl-
ated species of lower molecular weight were sometimes
detected among the immunoprecipitated proteins from
recombinant-infected cells. Some ofthese may correspond to
partially glycosylated precursors of the mature G protein,
such as the Mr 45,000 species identified by Gruber and Levine
(14), and a study of these intermediates may elucidate the
pathways of processing and transport of the maturing G
protein. Since about 60%6 of the mass of G glycoprotein is
contributed by carbohydrate, the size and cell-surface
expression of the mature protein made in recombinant-
infected cells suggest that its posttranslational processing and
transport were normal. At present, little is known of the
detailed mechanism of 0-glycosylation or the pathway fol-
lowed by this type of glycoprotein from its site of synthesis
to the plasma membrane. In addition, much remains to be
discovered about how a protein with only a single, internal,
hydrophobic domain becomes inserted and anchored in the
membrane. The development of the recombinant vectors
described above will allow us to address many of these
important questions. The vectors will be of value also in
examining the immune response to RS virus infection. For
reasons that are not understood, natural infection with the
virus frequently fails to confer immunity, a fact with serious
medical consequences. The ability of the recombinants
described above to elicit humoral and cell-mediated immu-
nity to RS virus is currently under investigation. With these
recombinants and with analogous vectors under development
in our laboratories that express the RS virus F protein, we
should be able to dissect the several components of the
immune response to RS virus and perhaps evolve a vacci-
nation strategy that will confer reliable protection from
infection.
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